tradingkey.logo

Medical device maker AngioDynamics beats Q4 revenue estimates

ReutersJul 15, 2025 10:40 AM


Overview

  • AngioDynamics fiscal Q4 net sales rose 12.7%, beating analyst expectations, per LSEG data

  • Adjusted EPS for fiscal Q4 beat analyst estimates, per LSEG data

  • Co generated $16.2 mln free cash flow in Q4 due to strong growth


Outlook

  • AngioDynamics sees FY2026 net sales $305 - $310 mln

  • Company expects Med Tech net sales growth of 12% - 15%

  • AngioDynamics forecasts flat Med Device net sales growth

  • Company anticipates FY2026 gross margin 53.5% - 55.5%


Result Drivers

  • MED TECH GROWTH - AngioDynamics reported a 22% increase in Med Tech net sales, driven by innovative platform technologies, per CEO Jim Clemmer

  • OPERATIONAL EFFICIENCY - Positive adjusted EBITDA and $16.2 million free cash flow attributed to operational efficiency efforts

  • TARIFF HEADWINDS - Tariffs impacted gross margin by 204 basis points, but strategies are in place to mitigate future impacts


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q4 Sales

Beat

$80.20 mln

$74.30 mln (3 Analysts)

Q4 Adjusted EPS

Beat

-$0.03

-$0.12 (3 Analysts)

Q4 Adjusted Net Income

Beat

-$1 mln

-$4.97 mln (3 Analysts)

Q4 Net Income

-$6.10 mln

Q4 Adjusted EBITDA

$3.40 mln

Q4 Gross Margin

52.7%


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

  • Wall Street's median 12-month price target for AngioDynamics Inc is $16.00, about 39.8% above its July 14 closing price of $9.63

Press Release: ID:nBw8z4ZD8a

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI